WHO Still Backs Paxlovid In COVID-19 But Advises Against New Antiviral Deuremidevir
The limitations of vaccines against COVID-19 mean that there is a need for new treatments for the disease, according to the organization.
You may also be interested in...
Top-line results for two newly approved COVID-19 antivirals in China showed roughly 1.5- to two-day cuts in median time to symptom resolution or recovery in mild-to-moderate Omicron patients versus placebo.
Members of the European Parliament were told that once the list was out, work would begin on identifying the products most vulnerable to supply chain problems.
Members of the European Parliament committee charged with leading the negotiations on the review of the EU pharmaceutical legislation have been presented with a study backing cuts in data protection and wider joint procurement of medicines outside emergency situations.